<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Metavia Inc. — News on 6ix</title>
<link>https://6ix.com/company/metavia-inc</link>
<description>Latest news and press releases for Metavia Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/metavia-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359eb378dffbe2df108238.webp</url>
<title>Metavia Inc.</title>
<link>https://6ix.com/company/metavia-inc</link>
</image>
<item>
<title>MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-doses-the-first-patient-in-higher-dose-phase-1-study-of-da-1726-its-glp-1-and-glucagon-dual-agonist-for-the-treatment-of-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-doses-the-first-patient-in-higher-dose-phase-1-study-of-da-1726-its-glp-1-and-glucagon-dual-agonist-for-the-treatment-of-obesity</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy AdultsCAMBRIDGE, Mass., April 10,</description>
</item>
<item>
<title>MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-reports-year-end-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-reports-year-end-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned</description>
</item>
<item>
<title>MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-advances-glp-1-based-obesity-program-with-irb-approval-for-higher-dose-phase-1-studies-of-da-1726-a-glp-1-and-glucagon-dual-agonist-demonstrating-best-in-class-potential-for-weight-loss-and-glucose-control</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-advances-glp-1-based-obesity-program-with-irb-approval-for-higher-dose-phase-1-studies-of-da-1726-a-glp-1-and-glucagon-dual-agonist-demonstrating-best-in-class-potential-for-weight-loss-and-glucose-control</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy AdultsCAMBRIDGE, Mass., March 18,</description>
</item>
<item>
<title>MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-expands-global-patent-protection-for-vanoglipel-supporting-metabolic-and-liver-disease-therapy-through-2035-4</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-expands-global-patent-protection-for-vanoglipel-supporting-metabolic-and-liver-disease-therapy-through-2035-4</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Patent Portfolio Includes 48 Granted and Pending Patents in the U.S., Europe, Japan, China and other Countries, Providing Protection Into 2035, Unless</description>
</item>
<item>
<title>MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum</guid>
<pubDate>Wed, 04 Mar 2026 13:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET.</description>
</item>
<item>
<title>MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-highlight-novel-obesity-metabolic-140100605</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-highlight-novel-obesity-metabolic-140100605</guid>
<pubDate>Tue, 17 Feb 2026 14:01:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET.</description>
</item>
<item>
<title>MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-builds-comprehensive-global-patent-133100073</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-builds-comprehensive-global-patent-133100073</guid>
<pubDate>Fri, 13 Feb 2026 13:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders. This currently includes 39 granted and pending patents in the U.S. and internationall</description>
</item>
<item>
<title>MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-announces-positive-ai-modeling-130000793</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-announces-positive-ai-modeling-130000793</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial intelligence (AI)-driven drug discovery company, leveraging their proprietary DeepMatcher® platform.</description>
</item>
<item>
<title>MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726…</title>
<link>https://6ix.com/company/metavia-inc/news/mtva-positive-results-for-48-mg-cohort-in-phase-1b-trial-of-da-1726</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/mtva-positive-results-for-48-mg-cohort-in-phase-1b-trial-of-da-1726</guid>
<pubDate>Wed, 21 Jan 2026 11:30:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Results for 8-week 48 mg Cohort in Phase 1b Trial of DA-1726 On January 5, 2026, MetaVia, Inc. (NASDAQ:MTVA) announced positive and statistically significant results from the 8-week 48 mg cohort from the Phase 1b trial of DA-1726, the company’s dual oxyntomodulin analog that functions as a glucagon-like</description>
</item>
<item>
<title>MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-announces-closing-9-3-210100376</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-announces-closing-9-3-210100376</guid>
<pubDate>Fri, 16 Jan 2026 21:01:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise</description>
</item>
<item>
<title>MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-announces-pricing-8-1-143200531</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-announces-pricing-8-1-143200531</guid>
<pubDate>Thu, 15 Jan 2026 14:32:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise o</description>
</item>
<item>
<title>MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-reports-positive-statistically-significant-133000698</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-reports-positive-statistically-significant-133000698</guid>
<pubDate>Mon, 05 Jan 2026 13:30:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. The results</description>
</item>
<item>
<title>MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-participate-sponsor-10th-annual-133100715</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-participate-sponsor-10th-annual-133100715</guid>
<pubDate>Mon, 29 Dec 2025 13:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah.</description>
</item>
<item>
<title>MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-regains-compliance-nasdaq-minimum-133100881</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-regains-compliance-nasdaq-minimum-133100881</guid>
<pubDate>Mon, 22 Dec 2025 13:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listi</description>
</item>
<item>
<title>MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD…</title>
<link>https://6ix.com/company/metavia-inc/news/mtva-new-data-for-vanoglipel-da-1241-presented-at-aasld</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/mtva-new-data-for-vanoglipel-da-1241-presented-at-aasld</guid>
<pubDate>Thu, 11 Dec 2025 15:41:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update New Data from Phase 2a Trial of Vanoglipel (DA-1241) Presented at The Liver Meeting 2025 In November 2025, MetaVia, Inc. (NASDAQ:MTVA) announced new data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented in a poster session at the American Association for the Study of Liver Diseases (AASLD) The</description>
</item>
<item>
<title>MetaVia Inc. Announces 1-for-11 Reverse Stock Split</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-inc-announces-1-11-134500089</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-inc-announces-1-11-134500089</guid>
<pubDate>Tue, 02 Dec 2025 13:45:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001 ("common stock"), effective at 5:00 p.m. Eastern Time on December 4, 2025. Beginning on December 5, 2025, the common stock will trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis.</description>
</item>
<item>
<title>MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-presents-positive-phase-2a-133100705</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-presents-positive-phase-2a-133100705</guid>
<pubDate>Fri, 07 Nov 2025 13:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of positive new data from its Phase 2a clinical trial evaluating vanoglipel (DA-1241), a potent and selective G protein-coupled receptor 119 (GPR119) agonist, as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH). The data highlight vanoglipel's differentiated dual activity across both hepatic and metabolic pathways,</description>
</item>
<item>
<title>MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-reports-third-quarter-2025-133100648</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-reports-third-quarter-2025-133100648</guid>
<pubDate>Thu, 06 Nov 2025 13:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate strategic update.</description>
</item>
<item>
<title>MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-present-phase-1-pre-210100372</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-present-phase-1-pre-210100372</guid>
<pubDate>Tue, 04 Nov 2025 21:01:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), in two poster presentations at ObesityWeek® 2025, taking place in-person and virtually November 4-7, 2025 in Atlanta, GA. The Phase 1 data demonstrated favorab</description>
</item>
<item>
<title>MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting</title>
<link>https://6ix.com/company/metavia-inc/news/metavia-announces-poster-presentation-vanoglipel-123100373</link>
<guid isPermaLink="true">https://6ix.com/company/metavia-inc/news/metavia-announces-poster-presentation-vanoglipel-123100373</guid>
<pubDate>Mon, 27 Oct 2025 12:31:00 GMT</pubDate>
<description>MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025, taking place November 7-11, 2025 in Washington, D.C.</description>
</item>
</channel>
</rss>